People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology, Pharmaceuticals, Other, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tyra Biosciences, Inc. | — | Biotechnology | Series D+ | $200.0M | $2.5B | 2024 |
| Checkmate Pharmaceuticals, Inc. | — | Biotechnology | Series C | $185.1M | $3.5B | 2019 |
| Amplyx Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $116.6M | $3.2B | 2017 |
| Healionics CORP | — | Other | Series A | $18.4M | $5.8M | 2011 |
| Naviscan, Inc | — | Other Health Care | Seed | $5.9M | $24.8M | 2009 |
Alan Fuhrman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alan Fuhrman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Powell | 1 | 14 |
| Corey Goodman | 1 | 13 |
| Edward Mathers | 1 | 12 |
| Robert Weisskoff | 1 | 12 |
| Ed Mathers | 1 | 11 |
| Nina Kjellson | 1 | 11 |
| Michael Grey | 1 | 10 |
| Ben Auspitz | 1 | 9 |
| Robert More | 1 | 7 |
| ANAND MEHRA | 1 | 7 |
| MICHAEL J. WARD | 1 | 5 |
| Paul Grint | 1 | 5 |
| Keith Flaherty | 1 | 5 |
| Mitchell Mutz | 1 | 5 |
| Johan Kordel | 1 | 4 |
| Peter Colabuono | 1 | 4 |
| Karen Talmadge | 1 | 3 |
| Paul J Mirabella | 1 | 3 |
| Timothy Mills | 1 | 3 |
| Andrew Marshall | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.